GW Pharma MS drug gets German approval

GW Pharmaceuticals has been given a lift after German authorities gave the thumbs up to its multiple sclerosis drug Sativex.

The firm, and its partner Almirall, claim Savitex can help treat moderate to severe spasticity in patients with MS.

The German drug regulators agree, although they say there is only "a minor added benefit".

MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

"We are pleased by the positive decision of the G-BA, which recognises that Sativex has an important role to play in meeting the needs of patients with spasticity due to multiple sclerosism," said Farid Taha, Managing Director of Almirall Hermal GmbH.

"Whilst the G-BA has defined the benefit as minor, we believe that Sativex offers a substantial benefit to patients and we now look forward to the meeting with the pricing authorities as the next step in this process."

GW's stock was up 2.7% at 8:42.

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.